Custom-Made vaccine trains immune system to fight advanced cancers
NCT ID NCT05098210
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-phase trial is testing whether a personalized vaccine made from each patient's unique tumor proteins can safely boost the immune system against advanced breast cancer, melanoma, and lung cancer. The vaccine is given along with an immune-boosting drug (nivolumab) and an adjuvant (poly ICLC). The study enrolls 25 adults whose cancers have spread or not responded to prior treatments. The main goal is to check for side effects and see if the vaccine can be made in time for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized peptide vaccine (neoantigen vaccine) plus nivolumab and poly ICLC
What this could lead to
If successful, this could point toward a new way to train the immune system to attack advanced cancers that have not responded to other treatments.
What could go wrong
This is a very early phase 1 trial with only 25 participants, so the main goal is safety, not effectiveness. The vaccine is custom-made for each person, which is complex and may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.